Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Helmi L. Lutsep

doi:10.2174/1568007053544165

Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Helmi L. Lutsep

Neurology

Research output: Contribution to journal › Review article › peer-review

11 Scopus citations

Abstract

Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

Original language	English (US)
Pages (from-to)	119-120
Number of pages	2
Journal	Current Drug Targets: CNS and Neurological Disorders
Volume	4
Issue number	2
DOIs	https://doi.org/10.2174/1568007053544165
State	Published - Apr 2005

Keywords

Acute stroke treatment
Infarct
Ischemia
Neuroprotectant
Neuroprotection
Repinotan

ASJC Scopus subject areas

General Neuroscience
Pharmacology

Access to Document

10.2174/1568007053544165

Cite this

@article{c850a5d6e2984656b08ed11ed5e88c70,

title = "Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke",

abstract = "Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.",

keywords = "Acute stroke treatment, Infarct, Ischemia, Neuroprotectant, Neuroprotection, Repinotan",

author = "Lutsep, {Helmi L.}",

year = "2005",

month = apr,

doi = "10.2174/1568007053544165",

language = "English (US)",

volume = "4",

pages = "119--120",

journal = "Current Drug Targets: CNS and Neurological Disorders",

issn = "1568-007X",

publisher = "Bentham Science Publishers B.V.",

number = "2",

}

TY - JOUR

T1 - Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

AU - Lutsep, Helmi L.

PY - 2005/4

Y1 - 2005/4

N2 - Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

AB - Serotonin agonists can reduce glutamate-induced excitotoxicity in cerebral ischemia. The potent 5-HT1A agonist BAY × 3702, or repinotan, has reduced cortical infarct volume in pre-clinical models even when given 5 hours after injury. Early clinical trials showed that the drug was safe, and displayed primarily serotonergic side effects such as nausea and vomiting. A phase IIb trial in moderate to moderately severe strokes completed enrollment in June 2004.

KW - Acute stroke treatment

KW - Infarct

KW - Ischemia

KW - Neuroprotectant

KW - Neuroprotection

KW - Repinotan

UR - http://www.scopus.com/inward/record.url?scp=18044387563&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044387563&partnerID=8YFLogxK

U2 - 10.2174/1568007053544165

DO - 10.2174/1568007053544165

M3 - Review article

C2 - 15857296

AN - SCOPUS:18044387563

SN - 1568-007X

VL - 4

SP - 119

EP - 120

JO - Current Drug Targets: CNS and Neurological Disorders

JF - Current Drug Targets: CNS and Neurological Disorders

IS - 2

ER -

Repinotan, A 5-HT1A agonist, in the treatment of acute ischemic stroke

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this